Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | SCN4A | P35499 | 9/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SCN1A | P35498 | 2/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169999 | 1.00 | L3MBTL1 (0.59) | L3MBTL1SCN4ATSHRLMNASCN1A | |
| SCHEMBL29423871 | 1.00 | L3MBTL1 (0.59) | L3MBTL1SCN4ATSHRLMNASCN1A | |
| SCHEMBL1679987 | 0.90 | L3MBTL1 (0.49) | L3MBTL1SCN4ATSHRLMNASCN1A | |
| SCHEMBL28263784 | 0.87 | L3MBTL1 (0.46) | L3MBTL1SCN4ATSHRLMNASCN1A | |
| SCHEMBL15384653 | 0.85 | L3MBTL1 (0.45) | L3MBTL1SCN4ATSHRLMNASCN1A | |
| SCHEMBL24394204 | 0.84 | L3MBTL1 (0.62) | L3MBTL1SCN4ATSHRLMNASCN1A | |
| SCHEMBL2775067 | 0.81 | L3MBTL1 (0.39) | L3MBTL1LMNACYP1A2CYP3A4KDM4E | |
| SCHEMBL24849514 | 0.81 | L3MBTL1 (0.59) | L3MBTL1SCN4ATSHRLMNASCN1A | |
| SCHEMBL5062924 | 0.79 | TDP1 (0.46) | L3MBTL1SCN4AKDM4EALDH1A1HPGD | |
| SCHEMBL5058437 | 0.79 | TDP1 (0.46) | L3MBTL1SCN4AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036918-A1 | PEPTIDE DERIVATIVE | Vexon, Inc. (JP) | 2009-03-18 | — | — | EP | claimed |
| US-20080009448-A1 | Peptide Derivative | VEXON, INC. (50%) (JP) | 2008-01-10 | — | — | US | claimed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| WO-2017195069-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| EP-2036918-A1 | PEPTIDE DERIVATIVE | Vexon, Inc. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20080009448-A1 | Peptide Derivative | VEXON, INC. (50%) (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1587943-A1 | METHOD FOR PREPARING A (R)- OR (S)- FORM OF N-(2,6-DIMETHYL PHENYL) ALANINE AND A COUNTER ENANTIOMERIC FORM OF N-(2,6-DIMETHYL PHENYL) ALANINE ESTER THERETO USING ENZYME | LG Life Sciences Ltd. (KR) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004055195-A1 | METHOD FOR PREPARING A (R)- OR (S)- FORM OF N-(2,6-DIMETHYL PHENYL) ALANINE AND A COUNTER ENANTIOMERIC FORM OF N-(2,6-DIMETHYL PHENYL) ALANINE ESTER THERETO USING ENZYME | LG LIFE SCIENCES LTD. (KR) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | L3MBTL1 115/4885SCN4A 3371/4885TSHR 2439/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | L3MBTL1 115/4885SCN4A 3371/4885TSHR 2439/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | L3MBTL1 115/4885SCN4A 3371/4885TSHR 2439/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | L3MBTL1 115/4885SCN4A 3371/4885TSHR 2439/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | L3MBTL1 115/4885SCN4A 3371/4885TSHR 2439/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | L3MBTL1 115/4885SCN4A 3371/4885TSHR 2439/4885 |
| US-20080009448-A1 | Peptide Derivative | ARGLU1, NGLY1, NPR3 | L3MBTL1 901/4885SCN4A 314/4885TSHR 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.